Julie Min Jeung Paik, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Spinal Fractures | 6 | 2022 | 678 | 2.610 |
Why?
|
Renal Insufficiency, Chronic | 9 | 2023 | 2102 | 1.820 |
Why?
|
Polypharmacy | 3 | 2021 | 283 | 1.430 |
Why?
|
Diabetic Nephropathies | 3 | 2022 | 967 | 1.400 |
Why?
|
Hip Fractures | 3 | 2022 | 919 | 1.250 |
Why?
|
Geriatrics | 2 | 2022 | 389 | 1.160 |
Why?
|
Nephrology | 2 | 2019 | 248 | 1.110 |
Why?
|
Pharmacists | 3 | 2019 | 229 | 0.900 |
Why?
|
Fractures, Bone | 5 | 2023 | 1882 | 0.880 |
Why?
|
Diabetic Ketoacidosis | 2 | 2023 | 229 | 0.870 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 5 | 2023 | 264 | 0.850 |
Why?
|
Diabetes Mellitus, Type 2 | 11 | 2023 | 11403 | 0.810 |
Why?
|
Kidney Failure, Chronic | 4 | 2021 | 2515 | 0.780 |
Why?
|
Hyperkalemia | 1 | 2022 | 208 | 0.740 |
Why?
|
Renal Dialysis | 6 | 2021 | 1737 | 0.720 |
Why?
|
International Classification of Diseases | 2 | 2021 | 849 | 0.710 |
Why?
|
Kidney | 6 | 2023 | 7022 | 0.680 |
Why?
|
House Calls | 1 | 2020 | 155 | 0.680 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2022 | 257 | 0.660 |
Why?
|
Calcium | 4 | 2017 | 5758 | 0.630 |
Why?
|
Histamine H2 Antagonists | 1 | 2018 | 168 | 0.590 |
Why?
|
Veterans | 5 | 2022 | 2347 | 0.590 |
Why?
|
Hypoglycemic Agents | 8 | 2023 | 2766 | 0.580 |
Why?
|
Proton Pump Inhibitors | 2 | 2018 | 503 | 0.580 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2016 | 75 | 0.580 |
Why?
|
Inappropriate Prescribing | 1 | 2018 | 194 | 0.570 |
Why?
|
Parathyroid Hormone | 3 | 2012 | 1810 | 0.550 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3546 | 0.540 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 134 | 0.530 |
Why?
|
Waist Circumference | 1 | 2019 | 908 | 0.530 |
Why?
|
Glomerulosclerosis, Focal Segmental | 2 | 2015 | 349 | 0.510 |
Why?
|
Wrist Injuries | 1 | 2017 | 200 | 0.500 |
Why?
|
Cardiovascular Diseases | 7 | 2023 | 14701 | 0.500 |
Why?
|
Nephrotic Syndrome | 2 | 2015 | 372 | 0.500 |
Why?
|
Hyponatremia | 1 | 2016 | 289 | 0.470 |
Why?
|
Patient Care | 1 | 2019 | 626 | 0.460 |
Why?
|
Gout | 2 | 2017 | 554 | 0.460 |
Why?
|
Body Mass Index | 4 | 2019 | 12527 | 0.450 |
Why?
|
Osteoporotic Fractures | 1 | 2017 | 383 | 0.440 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1624 | 0.420 |
Why?
|
Heart Failure | 4 | 2023 | 10378 | 0.420 |
Why?
|
Osteoporosis | 2 | 2021 | 1566 | 0.400 |
Why?
|
Hyperthyroidism | 1 | 2012 | 285 | 0.380 |
Why?
|
Dietary Supplements | 2 | 2014 | 3227 | 0.380 |
Why?
|
Medication Adherence | 2 | 2022 | 2015 | 0.370 |
Why?
|
Calcium, Dietary | 1 | 2012 | 526 | 0.360 |
Why?
|
Phosphorus | 1 | 2010 | 334 | 0.350 |
Why?
|
Aged | 27 | 2022 | 161379 | 0.340 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2020 | 1774 | 0.310 |
Why?
|
Bone Density | 2 | 2017 | 3433 | 0.300 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11531 | 0.290 |
Why?
|
Cohort Studies | 16 | 2023 | 39883 | 0.290 |
Why?
|
Glucocorticoids | 2 | 2015 | 2085 | 0.280 |
Why?
|
Humans | 54 | 2023 | 725001 | 0.280 |
Why?
|
Frail Elderly | 2 | 2022 | 654 | 0.280 |
Why?
|
Bone Density Conservation Agents | 1 | 2012 | 767 | 0.260 |
Why?
|
Glomerular Filtration Rate | 3 | 2023 | 2127 | 0.260 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4070 | 0.260 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1606 | 0.250 |
Why?
|
Geriatric Assessment | 3 | 2022 | 1332 | 0.250 |
Why?
|
Stroke | 3 | 2022 | 9569 | 0.250 |
Why?
|
Nurses | 2 | 2015 | 2446 | 0.240 |
Why?
|
Prospective Studies | 10 | 2020 | 51853 | 0.240 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2016 | 149 | 0.230 |
Why?
|
Telemedicine | 1 | 2020 | 2733 | 0.230 |
Why?
|
Algorithms | 2 | 2021 | 13759 | 0.230 |
Why?
|
Female | 34 | 2023 | 375303 | 0.220 |
Why?
|
Silicates | 1 | 2022 | 42 | 0.220 |
Why?
|
Pruritus | 2 | 2015 | 345 | 0.210 |
Why?
|
Minerals | 1 | 2023 | 262 | 0.210 |
Why?
|
Adult | 22 | 2023 | 211523 | 0.200 |
Why?
|
Snoring | 1 | 2022 | 176 | 0.190 |
Why?
|
Hydromorphone | 1 | 2021 | 64 | 0.190 |
Why?
|
Risk Assessment | 6 | 2021 | 23178 | 0.190 |
Why?
|
Self Report | 3 | 2022 | 3410 | 0.190 |
Why?
|
Glucosides | 2 | 2021 | 387 | 0.180 |
Why?
|
United States | 18 | 2023 | 68433 | 0.180 |
Why?
|
Hypertension | 2 | 2016 | 8250 | 0.180 |
Why?
|
Phosphates | 1 | 2023 | 792 | 0.180 |
Why?
|
Education, Pharmacy | 1 | 2019 | 36 | 0.180 |
Why?
|
Middle Aged | 23 | 2023 | 212155 | 0.180 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 42 | 0.180 |
Why?
|
Risk Factors | 13 | 2021 | 70971 | 0.170 |
Why?
|
Lithium | 1 | 2022 | 589 | 0.170 |
Why?
|
Calcium Phosphates | 1 | 2019 | 171 | 0.160 |
Why?
|
Cold Ischemia | 1 | 2018 | 66 | 0.160 |
Why?
|
Fentanyl | 1 | 2021 | 405 | 0.160 |
Why?
|
Incidence | 8 | 2018 | 20743 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2019 | 674 | 0.160 |
Why?
|
Chelating Agents | 1 | 2019 | 382 | 0.160 |
Why?
|
Vitamin D | 3 | 2018 | 3177 | 0.160 |
Why?
|
Vitamin A | 2 | 2011 | 625 | 0.160 |
Why?
|
Benzhydryl Compounds | 2 | 2021 | 766 | 0.150 |
Why?
|
Hearing | 1 | 2021 | 463 | 0.150 |
Why?
|
Prospective Payment System | 1 | 2018 | 134 | 0.150 |
Why?
|
Publication Bias | 1 | 2017 | 155 | 0.150 |
Why?
|
Pilot Projects | 2 | 2020 | 8099 | 0.150 |
Why?
|
Thrombotic Microangiopathies | 1 | 2018 | 123 | 0.150 |
Why?
|
Metformin | 1 | 2023 | 805 | 0.140 |
Why?
|
Diphosphonates | 1 | 2021 | 617 | 0.140 |
Why?
|
Hyperparathyroidism | 1 | 2017 | 338 | 0.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3169 | 0.130 |
Why?
|
Proteinuria | 2 | 2015 | 635 | 0.130 |
Why?
|
Administration, Oral | 2 | 2021 | 3907 | 0.130 |
Why?
|
Tissue and Organ Harvesting | 1 | 2018 | 370 | 0.130 |
Why?
|
Polymers | 1 | 2022 | 1622 | 0.130 |
Why?
|
Male | 19 | 2023 | 346964 | 0.130 |
Why?
|
Needs Assessment | 1 | 2020 | 1124 | 0.120 |
Why?
|
Medicare | 6 | 2022 | 6257 | 0.120 |
Why?
|
Body Size | 1 | 2017 | 456 | 0.120 |
Why?
|
Comorbidity | 2 | 2020 | 10246 | 0.120 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12937 | 0.120 |
Why?
|
Drug Interactions | 1 | 2018 | 1448 | 0.120 |
Why?
|
Hearing Loss | 1 | 2021 | 744 | 0.120 |
Why?
|
Suicide, Attempted | 1 | 2022 | 1165 | 0.120 |
Why?
|
Atrial Fibrillation | 2 | 2022 | 4827 | 0.120 |
Why?
|
Interviews as Topic | 1 | 2020 | 2542 | 0.120 |
Why?
|
Spine | 1 | 2020 | 1108 | 0.120 |
Why?
|
Interprofessional Relations | 1 | 2019 | 1009 | 0.110 |
Why?
|
Bone and Bones | 1 | 2023 | 2564 | 0.110 |
Why?
|
Ultraviolet Rays | 1 | 2017 | 1058 | 0.110 |
Why?
|
Kidney Calculi | 1 | 2015 | 444 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1553 | 0.100 |
Why?
|
Hospitalization | 2 | 2022 | 9956 | 0.100 |
Why?
|
Sex Factors | 2 | 2017 | 10385 | 0.100 |
Why?
|
Age Factors | 3 | 2019 | 18337 | 0.100 |
Why?
|
Mexican Americans | 1 | 2011 | 165 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2022 | 13692 | 0.100 |
Why?
|
Antihypertensive Agents | 2 | 2021 | 2000 | 0.090 |
Why?
|
Uric Acid | 2 | 2016 | 756 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1876 | 0.090 |
Why?
|
Pain Measurement | 1 | 2019 | 3423 | 0.090 |
Why?
|
Aspirin | 1 | 2021 | 3209 | 0.090 |
Why?
|
Kidney Diseases | 1 | 2019 | 2114 | 0.080 |
Why?
|
Massachusetts | 1 | 2020 | 8555 | 0.080 |
Why?
|
Atherosclerosis | 1 | 2022 | 3268 | 0.070 |
Why?
|
Demography | 1 | 2011 | 1625 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2933 | 0.070 |
Why?
|
Glucose | 3 | 2023 | 4315 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2903 | 0.070 |
Why?
|
Databases, Factual | 1 | 2021 | 7681 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 9589 | 0.070 |
Why?
|
Sleep | 1 | 2022 | 4407 | 0.070 |
Why?
|
Health Surveys | 1 | 2016 | 4002 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 14955 | 0.070 |
Why?
|
Aged, 80 and over | 2 | 2021 | 57615 | 0.070 |
Why?
|
Graft Rejection | 1 | 2018 | 4376 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5522 | 0.060 |
Why?
|
Bipolar Disorder | 1 | 2022 | 4861 | 0.060 |
Why?
|
Diet | 2 | 2014 | 7797 | 0.060 |
Why?
|
Seasons | 1 | 2010 | 1469 | 0.060 |
Why?
|
Depressive Disorder, Major | 1 | 2022 | 4420 | 0.060 |
Why?
|
Creatinine | 2 | 2023 | 1889 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3708 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9697 | 0.060 |
Why?
|
Prevalence | 1 | 2020 | 14951 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5059 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2018 | 4166 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2022 | 74145 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12244 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 87 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40178 | 0.050 |
Why?
|
Iohexol | 1 | 2023 | 198 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14713 | 0.050 |
Why?
|
Sulfonylurea Compounds | 1 | 2023 | 186 | 0.050 |
Why?
|
Cystatin C | 1 | 2023 | 258 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5894 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12318 | 0.050 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2021 | 77 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10968 | 0.050 |
Why?
|
Hydrochlorothiazide | 1 | 2021 | 99 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5217 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 7859 | 0.050 |
Why?
|
Audiometry | 1 | 2021 | 242 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2011 | 24043 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 55791 | 0.050 |
Why?
|
Life Style | 1 | 2011 | 3780 | 0.050 |
Why?
|
Exercise | 1 | 2016 | 5489 | 0.040 |
Why?
|
Health Status | 1 | 2012 | 3984 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 6082 | 0.040 |
Why?
|
Antimanic Agents | 1 | 2022 | 505 | 0.040 |
Why?
|
Sodium | 1 | 2022 | 1591 | 0.040 |
Why?
|
Pyridones | 1 | 2021 | 691 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2021 | 862 | 0.040 |
Why?
|
Adolescent | 2 | 2021 | 84411 | 0.040 |
Why?
|
Maine | 1 | 2016 | 140 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2015 | 38720 | 0.030 |
Why?
|
Furosemide | 1 | 2015 | 169 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2259 | 0.030 |
Why?
|
Suicidal Ideation | 1 | 2022 | 1164 | 0.030 |
Why?
|
Propensity Score | 1 | 2019 | 1747 | 0.030 |
Why?
|
Pyrazoles | 1 | 2021 | 1926 | 0.020 |
Why?
|
Calcinosis | 1 | 2019 | 1464 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4388 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4939 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2015 | 785 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2022 | 3012 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2022 | 11885 | 0.020 |
Why?
|
Graft Survival | 1 | 2018 | 3726 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 5932 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4421 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10244 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2021 | 61674 | 0.010 |
Why?
|
Registries | 1 | 2018 | 7910 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 6196 | 0.010 |
Why?
|